Metabolites, including SCFAs, have shown potential in alleviating symptoms of AD by reducing Aβ deposition and tau hyperphosphorylation, inhibiting neuroinflammation, improving blood-brain barrier integrity, and regulating neuroendocrine functions. This evidence concerns the gene MAPT and Alzheimer disease.